Patients with chronic pain on opioid therapy taking dronabinol: Incidence of false negatives using radioimmunoassay

Journal of Opioid Management

Volumn 4, Issue 1, 2008, Pages 21-26

  Narang, Sanjeet ^a   Wasan, Ajay D ^a   Ross, Edgar L ^a   Michna, Edward ^a   Chen, Jui Yuan ^b   Jamison, Robert N ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b SHIN KONG WU HO SU MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Cannabinoids; Chronic pain; Dronabinol; Marijuana; Marinol; Opioids; Radioimmuno assay; Serum blood screening

Indexed keywords

CANNABINOID; CANNABIS; DRONABINOL; PLACEBO; TETRAHYDROCANNABINOL;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; BRIEF PAIN INVENTORY; CHRONIC PAIN; CLINICAL ARTICLE; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DOUBLE BLIND PROCEDURE; DRUG ANALYSIS; DRUG EFFICACY; DRUG MEGADOSE; DRUG METABOLISM; FALSE NEGATIVE RESULT; FEMALE; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; IMMUNOASSAY; LOW DRUG DOSE; MALE; MORNING DOSAGE; QUESTIONNAIRE; RADIOIMMUNOASSAY; SEX DIFFERENCE; SINGLE DRUG DOSE;

EID: 41549136912     PISSN: 15517489     EISSN: None     Source Type: Journal    
DOI: 10.5055/jom.2008.0004     Document Type: Article

References (16)

1. Michna E, Ross EL, Hynes WL, et al.: Predicting aberrant drug behavior in patients treated for chronic pain: Importance of abuse history. J Pain Symp Manage. 2004; 28: 250-258.
2. Michna E, Jamison RN, Pham LD, et al.: The utility of urine toxicology screening in monitoring opioid therapy adherence among chronic pain patients. Clin J Pain. 2007; 23: 173-179.
3. Substance Abuse and Mental Health Services Administration (SAMHSA): Results from the 2005 national survey on drug use and health: National findings. Available at www.oas.samhsa.gov. Accessed May 12, 2007.
4. Fishbain D, Rosomoff HL, Rosomoff RS: Drug Abuse, dependence, and addiction in chronic pain patients. Clin J Pain. 1992; 8: 77-85.
5. Ware MA, Doyle CR, Woods R, et al.: Cannabis use for chronic non-cancer pain: Results of a prospective survey. Pain. 2003; 102: 211-216.
6. Narang S, Gibson D, Wasan AD, et al.: Efficacy of dronabinol as an adjuvant treatment for chronic pain patients on opioid therapy. J Pain. 2008 (in press).
7. Cleeland C, Gonin R, Hatfiled AK, et al.: Pain and its treatment in outpatients with metastatic cancer. N Engl J Med. 1994; 330: 592-596.
8. Tan G, Jensen MP, Thomby JI, et al.: Validation of the brief pain inventory for chronic nonmalignant pain. J Pain. 2004; 5: 133-137.
9. Zigmond A, Snaith RP: The Hospital Anxiety and Depression Scale. Acta Psychia Scand. 1983; 67: 361-370.
10. Bjelland I, Dahl AA, Haug TT, et al.: The validity of the Hospital Anxiety and Depression Scale: An updated literature review. J Psychosom Res. 2002; 52: 69-77.
11. Moorey S, Greer S, Watson M, et al.: The factor structure and factor stability of the Hospital Anxiety and Depression Scale in patients with cancer. Br J Psychia. 1991; 58: 255-259.
12. Cook CE, Seltzman HH, Schindler VH, et al.: Radioimmunoassays for cannabinoids. NIDA Res Monogr. 1982; 42: 19-32.
13. Yamamoto I, Watanabe K, Narimatsu S, et al.: Recent advances in the metabolism of cannabinoids. Intern J Biochem Cell Bio. 1995; 27: 741-746.
14. Manno J, Manno BR, Kemp PM, et al.: Temporal indication of marijuana use can be extimated from plasma and urine concentrations of delta9-tetrahydroconnabinal, 11-hydoxy-delta9-tetrahydrocannabinal, and 11-nor-delta9-tetrahydrocannabinal-9-carboxylic acid. J Anal Toxicol. 2001; 25: 538-549.
15. Goodwin R, Gustafson RA, Barnes A, et al.: Delta9-tetrahydrocannabinal, 11-hydroxy-delta9-tetrahydrocannabinol and 11-nor-9-carboxy-delta9-tetrahydrocannabinol in human plasma after controlling oral administration of cannabinoids. Ther Drug Monit. 2006; 28: 545-551.
16. Cone E, Huestis MA: Related blood concentrations of tetrahydrocannabinol and metabolites to pharmacologic effects and time of marijuana usage. Ther Drug Monit. 1993; 15: 527-532.